Having trouble viewing this email? View in your browser.

AstraZeneca is proud to be a diamond sponsor for the 34th ECCMID Congress.
As part of our presence, we will be hosting a COVID-19 specific, integrated symposium, as well as two innovation and pipeline theatre sessions.

We eagerly anticipate your participation in Barcelona or online through the ECCMID integrated platform!

Saturday 27 April 2024 I 12:15-13:15 (CEST) I Hall L

Despite vaccination, certain patient populations remain at a heightened risk of severe COVID-19 outcomes.

Join our expert-led session to delve into key data and discuss the continued importance of recognising and responding to COVID-19 risk in immunocompromised populations.

Yoav Keynan,

Associate Professor,
University of Manitoba,
Winnipeg, Canada

Marta Boffito,

Consultant Physician,
Chelsea and
Westminster Hospital,
London, UK

Paul Loubet,

Professor of Infectious
CHU Carémeau
& Montpellier University,
Nîmes, France


Sunday 28 April 2024 I 10:30-10:50 (CEST) I Innovation and Pipeline Theatre

Roger Paredes,

Head of Department
of Infectious Diseases,
Hospital Germans Trias,
Barcelona, Spain
Building on the symposium discussion, Dr Paredes will explore the ongoing burden of COVID-19 and the potential for targeted prevention strategies in immunocompromised patient populations.

Don't miss this opportunity to be part of the discussion!

Monday 29 April 2024 I 10:30-10:50 (CEST) I Innovation and Pipeline Theatre

, PhD

Global Medical Affairs
Head, Vaccines and
Immune Therapies,
AstraZeneca, US
Consider how innovations in vaccines and monoclonal antibodies are evolving to offer a complementary approach to protection from infectious diseases.
Learn more about AstraZeneca's commitment to reducing the global burden of infectious diseases through the development of transformative technologies.

These are non-promotional sessions organised and funded by AstraZeneca.

The information displayed during the meeting is exclusively for healthcare professionals empowered to prescribe or dispense medicinal products.

Please do not distribute in media, supporting materials or communication channels aimed at the general public.

La información mostrada durante la reunión está dirigida exclusivamente a Profesionales Sanitarios facultados para prescribir o dispensar medicamentos.

Por favor no distribuir en medios, soportes o canales de comunicación dirigidos a público general.

Vault ID: Z4-63606; Date of approval: April 2024.

©2024 AstraZeneca Global UK. 1 Francis Crick Avenue,
Cambridge, Cambridgeshire CB2 0RE, United Kingdom.

All rights reserved.

You have received this email as a contact of ESCMID or one of its affiliated societies.
You can unsubscribe here.